Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3； or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo； R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro； R4 is methyl or fluoro； m is 0, 1 or 2； E is a bond, or thiazolyl, optionally substituted with methyl or fluoro； A1 is CH or N, A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N； R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O&mdash；C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4alkoxy or F； R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.Jedinjenje formule IIagdeR2 je H ili ciklopropil；R3 je granat C2-C6 alkil ili C3-C6 cikloalkil, od koji je svaki izborno supstituisan sa jednim ili dva fluoro ili sa trifluorometilom； R4 je metil ili fluoro； m je 0, 1 ili 2；R5 je H, metil ili fluoro； R6 je C1-C6 alkil；ili njegova farmaceutski prihvatljiva so, N-oksid ili hidrat.Prijava sadrži još 16 patentnih zahteva.
